Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense

Rhino-conjunctivitis Clinical Trial

— Osiris  

Official title:

Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01425788
• Other study ID #: OS-G-01
• Status: Completed
• Phase: Phase 2
• First received: August 26, 2011
• Last updated: June 25, 2015
• Start date: August 2011
• Est. completion date: February 2012

Study information

• Verified date: June 2015
• Source: ALK-Abelló A/S
• Contact: n/a
• Is FDA regulated: No
• Health authority: Poland: The Central Register of Clinical Trials
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to investigate the tolerability of Osiris Phleum pratense used with 2 simplified up-dosing schedules compared to the up-dosing schedule used in current practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 236
• Est. completion date: February 2012
• Est. primary completion date: November 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent obtained before entering the trial

• Male or female >/= 18 years at visit 1

• A clinically relevant history of grass pollen induced allergic rhinoconjunctivitis (moderate to severe) and having received symptomatic treatment during grass pollen season 2010 and 2011

• Positive skin prick test response (wheal diameter >/= 3mm) to Phleum pratense

• Positive specific IgE against Phleum pratense (>/= 0,70KUL / class 2)

• Female subjects of childbearing potential must have a negative pregnancy test and be willing to practice appropriate contraceptive methods until Visit 4

• Subjects willing and able to comply with trial protocol regimen

Exclusion Criteria:

• Subjects included in another protocol (treatment intervention and/or investigational medicine product) or having participated in another clinical trial within 30 days prior to visit 1

• A clinically relevant history of symptomatic seasonal allergic rhinoconjunctivitis caused by an allergen (e.g. hazel, alder, birch, ash) to which the subject will be exposed during the 30-day treatment period.

• A clinically relevant medical history of symptomatic perennial allergy to allergen(s) to which the subject is regularly exposed (e.g. cat, house dust mites).

• Known sensitization (history of positive SPT) to food allergens with oral allergy syndrome

• Uncontrolled asthma (in accordance with GINA guidelines) within the last 12 months

• FEV < 60% of predicted within the last 12 months

• Severe asthma exacerbation(s) within the last 12 months

• A clinically relevant chronic disease (>/= 3 months) (e.g fibrosis, malignancy, type 1 diabetes mellitus, malabsorption or malnutrition, renal or hepatic insufficiency)

• Malignancy or systemic disease affecting the immune system (e.g. autoimmune disease, immune complex disease or immune deficiency disease)

• Inflammatory conditions in the oral cavity with severe symptoms such as oral lichen planus with ulcerations or severe oral mycosis or dental extraction at randomisation

• Medical history of recurrent urticaria or atopic dermatitis during the last 2 years

• Currently receiving treatment preventing the initiation of SIT (e.g. tricyclic antidepressants, mono amine oxidase inhibitors (MAOIs) and catechol-O-methyl transferase inhibitors (COMT inhibitors))

• History of allergy, hypersensitivity, or intolerance to the excipients of the investigational medicinal product

• Being immediate family of the investigator or trial staff, defined as the investigator's / staff's spouse, parent, grandparent, child or grandchild

• History of drug induced (incl. immunotherapy) facial angioedema (including experience of Quincke oedema) or a family (parents or siblings) history of hereditary angioedema

• Anticipated use of any prohibited medication within the specified time windows as defined in the protocol

• Previous treatment by immunotherapy with grass pollen for more than one month within the last 5 years

• Any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the trial evaluations or optimal participation

• History of anaphylaxis with cardio respiratory symptoms (e.g. food allergy, drugs or an idiopathic reaction)

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Conjunctivitis
• Rhino-conjunctivitis

Intervention

Biological:
• Osiris Phleum pratense

• Osiris Phleum pratense

• Osiris Phleum pratense

Locations

Country	Name	City	State
Poland	Poradnia Alergologii i Chorob Pluc Uniwersyteckiego Szpitala Klinicznego Nr1 im. N. Barlickiego w Lodzi	Lodz

Sponsors (4)

Lead Sponsor	Collaborator
ALK-Abelló A/S	ACM Pivotal Global Central Laboratory, Brecon Pharmaceuticals Ltd, Ergomed

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tolerability based on reporting of adverse events	Recording of adverse events are performed during the entire trial period, from screening to final follow-up contact.	An average of 42 days per subject	Yes
Secondary	Subject satisfaction	To compare the subjects' satisfaction of the different dosing schedules at end of the trial (after 30 days of treatment with trial medication).	Measured at "End of treatment/end of trial Visit"	No